Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma

This observational study evaluated the treatment outcomes of clinical factors on the patients with lung adenocarcinoma with epidermal growth factor receptor mutations who received tyrosine kinase inhibitors as first-line treatment. Patients with stage IIIb or IV lung adenocarcinoma with mutated epid...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chi-Cheng, Lin, Chih-Bin, Chu, Sung-Chao, Huang, Wei-Han, Lee, Jen-Jyh, Yang, Gee-Gwo, Wang, Tso-Fu, Wu, Yi-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373628/
https://www.ncbi.nlm.nih.gov/pubmed/32702917
http://dx.doi.org/10.1097/MD.0000000000021275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373628/
https://www.ncbi.nlm.nih.gov/pubmed/32702917
http://dx.doi.org/10.1097/MD.0000000000021275

Ejemplares similares